KINIKSA PHARMACEUTICALS INTERNATIO (KNSA)
Health Care · Biopharmaceuticals / Specialty therapeutics · NASDAQ
Kiniksa is a biopharmaceutical company commercializing ARCALYST (IL-1 cytokine trap) for recurrent pericarditis and rare inflammatory diseases, with a pipeline of next-generation IL-1R1 inhibitors in clinical development.
What KINIKSA PHARMACEUTICALS INTERNATIO does
Kiniksa is a biopharmaceutical company developing and commercializing novel therapies for diseases with unmet need, with a focus on cardiovascular indications. The company commercializes ARCALYST, an FDA-approved interleukin-1 (IL-1) cytokine trap licensed from Regeneron, for recurrent pericarditis, Cryopyrin-Associated Periodic Syndromes (CAPS), and Deficiency of Interleukin-1 Receptor Antagonist (DIRA). The company is advancing a pipeline of internally developed IL-1R1 inhibitors, including KPL-387 (monoclonal antibody in Phase 2/3 for recurrent pericarditis) and KPL-1161 (pre-clinical Fc-modified antibody designed for quarterly dosing).
Themes: ["IL-1 inhibition / inflammation"]
Fundamentals
- Price$65.38 as of 2026-07-09 close
- Market cap$5.0B as of 2026-07-10
- 1-year return+138.0% as of 2026-07-09 close
- P/E68.57 as of 2026-07-10
- Net margin+9.7% as of 2026-07-10
- Gross margin+89.3% as of 2026-07-10
- ROE+13.3% as of 2026-07-10
- Debt / equity0.00 as of 2026-07-10
- Revenue growth (YoY)+56.7% as of 2026-07-10
- Revenue CAGR (3y)+45.5% SEC XBRL
- Beta0.11 as of 2026-07-10
Key risks (from latest filing)
["Clinical trial execution risk: KPL-387 Phase 2/3 data expected H2 2026; failure to meet efficacy or safety endpoints could delay or halt development"]
Competitors & peers
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.